{"description":"The analysis dataset is comprised of all evaluable patients. One patient was lost to follow-up within 3 weeks of enrollment and was unevaluable.","eventGroups":[{"description":"Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression or up to 2 years.","id":"EG000","otherNumAffected":4,"otherNumAtRisk":17,"seriousNumAffected":0,"seriousNumAtRisk":17,"title":"Simvastatin"}],"frequencyThreshold":"1","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"1 grade 2","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17,"numEvents":1}],"term":"Elevated CPK"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"3 patients with grade 2","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE (3.0)","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":17,"numEvents":3}],"term":"Musculoskeletal pain"}],"timeFrame":"Assessed every 3 months on therapy up to day 30 post-therapy. Median duration on treatment was 6 months (range 1-24 months)."}